Adeno-associated virus (AAV) is a small, non-pathogenic, ssDNA packaged virus that is able to infect a wide range of vertebrate hosts, including humans. AAV belongs to the Parvovirinae subfamily of the Parvoviridae family and the Dependoparvovirus genus. As their name implies, they require co-infection with an adenovirus or herpesvirus as a helper virus for replication.
AAV packages a 4.7 kb genome that encodes nonstructural (rep), structural (cap), assembly activation (aap), and membrane-associated accessory (maap) proteins. The AAV capsid consists of a total of 60 viral protein (VP) molecules; a mixture of three overlapping gene products, VP1, VP2, and VP3, encoded by the cap open reading frame (ORF) and organized with T = 1 icosahedral symmetry. AAV has been widely used for gene therapy applications and offers several advantages over other viral vectors, including lower toxicity and the availability of more than 150 naturally occurring genotypes and serotypes. These serotypes differ in their tropism, allowing for targeted gene delivery to most tissues and cell types. Recombinant AAV (rAAV) packaged with the gene of interest (GOI) has been successfully used in clinical trials to treat a variety of rare genetic diseases.
Quiescent neural stem cells (qNSCs) with radial morphology are the only proven source of new neurons in the adult mammalian brain. Although various strategies have been developed to target and manipulate adult hippocampal qNSCs, they often suffer from long propagation times, low recombination efficiency, and nonspecific labeling. Therefore, there is an urgent need to develop an easily manufactured viral vector that allows for flexible packaging and stable expression of various transgenes in qNSCs. Here, researchers report a recombinant adeno-associated virus serotype 4 (rAAV4)-based toolkit that preferentially targets hippocampal qNSCs and allows lineage tracing, functional analysis, and activity manipulation of adult qNSCs. Importantly, targeting qNSCs in a non-Cre-dependent manner opens the possibility to study qNSCs in genetically refractory animal species and may have a translational impact in gene therapy by preferentially targeting qNSCs.
The researchers packaged the CMV-GFP/Cre plasmid into rAAV4 capsid to generate rAAV4-CMV-GFP/Cre (Figure 1A). rAAV4-CMV-GFP/Cre was injected into the DG of Ai9 reporter mice, which contain a loxP-flanked STOP cassette that prevents transcription of the downstream RFP variant (tdTomato) in the absence of Cre recombinase (Figure 1B). Three days after viral injection, the researchers examined the expression of GFP (for Cre expression) and tdTomato (for Cre-dependent recombination) in AAV4-labeled cells and observed that both GFP and tdTomato signals were strong, and all tdTomato+ cells co-localized with GFP (Figure 1C), indicating that Cre-mediated recombination using CMV-GFP/Cre is highly efficient. Importantly, the majority of rAAV4-labeled tdTomato+ cells were rNSCs (Figure 1D) and colocalized with NESTIN and GFAP markers (Figures 1E and 1F).
Figure 1. rAAV4 Allows for Genetic Manipulation of Quiescent NSCs in the Adult Hippocampus. (Crowther A J, et al., 2018)
The researchers injected rAAV4-CMV-GFP/Cre into another reporter line called mTmG, a dual fluorescent Cre reporter mouse that expresses membrane-targeted tdTomato (mT) before Cre-mediated excision and membrane-targeted GFP (mG) after excision (Figure 1G). Since GFP/Cre is localized in the nucleus, the membrane-targeted GFP signal around the NSC soma and radial processes in the mTmG reporter mouse indicated that recombination had occurred. rAAV4-GFP/Cre efficiently targeted rNSCs (Figure 1H), indicating that the rAAV4-Cre system can target rNSCs using different Cre-inducible reporter lines.
Customer Reviews
Great product!
I’ve used various viral vectors over the years, but the AAV4-Cre-GFP stands out in terms of quality and performance. The expression levels of Cre recombinase were impressive, and GFP fluorescence was easily detectable. Great product for any genetic engineering projects!
United Kingdom
04/19/2020
Write a Review